应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
06127 昭衍新药
未开盘 11-04 16:08:10
24.320
+3.200
+15.15%
最高
24.360
最低
20.640
成交量
1,131万
今开
21.000
昨收
21.120
日振幅
17.61%
总市值
182.16亿
流通市值
28.94亿
总股本
7.49亿
成交额
2.57亿
换手率
9.50%
流通股本
1.19亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）
资讯
新帖
简况
异动快报：昭衍新药（603127）11月4日14点10分触及涨停板
证券之星 · 11-04 14:11
异动快报：昭衍新药（603127）11月4日14点10分触及涨停板
异动解读｜昭衍新药盘中上涨6.34%，CXO板块走强叠加业绩预期改善
行情直击 · 11-04 13:31
异动解读｜昭衍新药盘中上涨6.34%，CXO板块走强叠加业绩预期改善
“猴戏”撑起十倍利润，昭衍新药创始人周志文套现逾14亿
凤凰网港股 · 11-04 13:24
“猴戏”撑起十倍利润，昭衍新药创始人周志文套现逾14亿
昭衍新药（603127）11月3日主力资金净卖出2.12亿元
证券之星 · 11-04 08:48
昭衍新药（603127）11月3日主力资金净卖出2.12亿元
昭衍新药（603127）披露H股10月月报表，11月03日股价下跌9.85%
证券之星 · 11-03 22:01
昭衍新药（603127）披露H股10月月报表，11月03日股价下跌9.85%
11月3日昭衍新药跌9.85%，医疗ETF华宝基金重仓该股
证券之星 · 11-03 16:44
11月3日昭衍新药跌9.85%，医疗ETF华宝基金重仓该股
昭衍新药更新10月股份变动月报表，股本维持稳定
公告速递 · 11-03 15:02
昭衍新药更新10月股份变动月报表，股本维持稳定
异动解读｜昭衍新药盘中下跌5.36%，业绩利好后资金分歧加大
行情直击 · 11-03 11:37
异动解读｜昭衍新药盘中下跌5.36%，业绩利好后资金分歧加大
昭衍新药（603127）11月2日主力资金净买入4197.14万元
证券之星 · 11-03 08:42
昭衍新药（603127）11月2日主力资金净买入4197.14万元
招银国际：上调昭衍新药(06127.HK)目标价至30港元 维持“买入”评级
智通财经 · 11-02 11:15
招银国际：上调昭衍新药(06127.HK)目标价至30港元 维持“买入”评级
招银国际：上调昭衍新药(06127)目标价至30港元 维持“买入”评级
智通财经 · 11-02 11:15
招银国际：上调昭衍新药(06127)目标价至30港元 维持“买入”评级
股市必读：九州通新发布《九州通关于与北京昭衍新药研究中心股份有限公司等签订《战略合作协议》的公告》
证券之星 · 11-02 02:56
股市必读：九州通新发布《九州通关于与北京昭衍新药研究中心股份有限公司等签订《战略合作协议》的公告》
昭衍新药（603127）2026年三季报简析：营收净利润同比双双增长，盈利能力上升
证券之星 · 10-31
昭衍新药（603127）2026年三季报简析：营收净利润同比双双增长，盈利能力上升
生物资产重估推高利润 昭衍新药前三季度净利增逾10倍
经济参考网 · 10-30
生物资产重估推高利润 昭衍新药前三季度净利增逾10倍
异动解读｜昭衍新药盘中上涨5.51%，战略合作与业绩改善共振
行情直击 · 10-30
异动解读｜昭衍新药盘中上涨5.51%，战略合作与业绩改善共振
昭衍新药：10月29日融资净买入2599.42万元，当日排名第49
同花顺 · 10-30
昭衍新药：10月29日融资净买入2599.42万元，当日排名第49
九州通最新公告：与昭衍新药等签订战略合作协议
证券之星 · 10-29
九州通最新公告：与昭衍新药等签订战略合作协议
异动解读｜昭衍新药盘中下跌5.39%，三季报利好落地后股价回落
行情直击 · 10-29
异动解读｜昭衍新药盘中下跌5.39%，三季报利好落地后股价回落
昭衍新药2026三季报净利暴增逾10倍，新签订单翻倍破34亿
时代周报 · 10-28
昭衍新药2026三季报净利暴增逾10倍，新签订单翻倍破34亿
昭衍新药（06127）董事会通过三季度报告并宣布11月5日举行业绩说明会
公告速递 · 10-28
昭衍新药（06127）董事会通过三季度报告并宣布11月5日举行业绩说明会
暂无数据
公司概况
公司名称：
昭衍新药
所属市场：
SEHK
上市日期：
--
主营业务：
北京昭衍新药研究中心股份有限公司是一家主要从事新药药理毒理学研究的中国公司。该公司通过三个分部开展业务。药物非临床研究服务分部主要提供药品非临床安全性评价服务、药效学研究服务、药代动力学研究服务。临床服务及其他分部主要提供药品上市前的临床服务以及药物警戒服务。实验模型供应分部为实验模型及其附属产品的生产和销售。该公司主要在中国国内和海外市场开展业务。
发行价格：
--
{"stockData":{"symbol":"06127","market":"HK","secType":"STK","nameCN":"昭衍新药","latestPrice":24.32,"timestamp":1793779690007,"preClose":21.12,"halted":0,"volume":11307580,"delay":0,"changeRate":0.15151515151515146,"floatShares":118995206,"shares":749000000,"eps":0.4703248077828339,"marketStatus":"未开盘","change":3.2,"latestTime":"11-04 16:08:10","open":21,"high":24.36,"low":20.64,"amount":257368656,"amplitude":0.176136,"askPrice":24.32,"askSize":15300,"bidPrice":24.24,"bidSize":500,"shortable":3,"etf":0,"ttmEps":1.7821383002824416,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1793842200000},"marketStatusCode":0,"adr":0,"listingDate":1614268800000,"exchange":"SEHK","adjPreClose":21.12,"dividendRate":0.005806,"openAndCloseTimeList":[[1793755800000,1793764800000],[1793768400000,1793779200000]],"volumeRatio":1.553981,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"603127","market":"SH","secType":"STK","nameCN":"昭衍新药","latestPrice":44.1,"timestamp":1793775600000,"preClose":40.09,"halted":0,"volume":48677400,"delay":0,"premium":"-53.10"}},"requestUrl":"/m/hq/s/06127/tweets","defaultTab":"tweets","newsList":[{"id":"2680408188","title":"异动快报：昭衍新药（603127）11月4日14点10分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2680408188","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680408188?lang=zh_cn&edition=full","pubTime":"2026-11-04 14:11","pubTimestamp":1793772671,"startTime":"0","endTime":"0","summary":"证券之星11月4日盘中消息，14点10分昭衍新药（603127）触及涨停板。其所属行业医疗服务目前上涨。领涨股为益诺思。该股为基因编辑，创新药，CAR-T疗法概念热股，当日基因编辑概念上涨4.49%，创新药概念上涨3.79%，CAR-T疗法概念上涨3.08%。11月3日的资金流向数据方面，主力资金净流出2.12亿元，占总成交额13.21%，游资资金净流入3727.61万元，占总成交额2.32%，散户资金净流入1.75亿元，占总成交额10.89%。近5日资金流向一览见下表：昭衍新药主要指标及行业内排名如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110400022400.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603127","06127","BK0216","BK1576","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132323379","title":"异动解读｜昭衍新药盘中上涨6.34%，CXO板块走强叠加业绩预期改善","url":"https://stock-news.laohu8.com/highlight/detail?id=1132323379","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1132323379?lang=zh_cn&edition=full","pubTime":"2026-11-04 13:31","pubTimestamp":1793770299,"startTime":"0","endTime":"0","summary":"11月4日，昭衍新药盘中上涨6.34%，报22.46港元，成交额9810.91万港元。本次异动主要受CXO板块整体走强及公司业绩预期改善带动。同板块中，药明生物上涨8.87%，药明康德上涨8.69%，药明合联上涨6.94%，显示资金正回流生命科学工具和服务板块。公司此前披露前三季度营收11.88亿元，同比增长20.60%，归母净利润9.30亿元，同比增长1051.94%；累计新签订单约34.2亿元，同比增长109%。同时，机构近日上调其目标价至30港元并维持买入评级，进一步强化了市场对其主业复苏的预期。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"昭衍新药上涨，CXO板块集体走强","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680608629","title":"“猴戏”撑起十倍利润，昭衍新药创始人周志文套现逾14亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2680608629","media":"凤凰网港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680608629?lang=zh_cn&edition=full","pubTime":"2026-11-04 13:24","pubTimestamp":1793769852,"startTime":"0","endTime":"0","summary":"凤凰网财经《公司研究院》近日，昭衍新药披露三季报：营收11.88亿元，同比增20.60%；归母净利润9.30亿元，同比增1051.94%；扣非净利8.81亿元，同比增2933.09%。前三季度新签订单34.2亿元，同比增109%；期末在手订单45亿元，同比增80%，三季度单季新签14亿元。02 实控人周志文多轮减持套现超14亿，顾氏姑侄近乎清仓离场除业绩结构外，股东减持是市场关注的另一条线索。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://original.ifeng.com/c/8xmDhrknYKd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["603127","BK1141","BK0216","06127","BK1576"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680701215","title":"昭衍新药（603127）11月3日主力资金净卖出2.12亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2680701215","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680701215?lang=zh_cn&edition=full","pubTime":"2026-11-04 08:48","pubTimestamp":1793753300,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年11月3日收盘，昭衍新药报收于40.09元，下跌9.85%，换手率6.16%，成交量38.65万手，成交额16.06亿元。11月3日的资金流向数据方面，主力资金净流出2.12亿元，占总成交额13.21%，游资资金净流入3727.61万元，占总成交额2.32%，散户资金净流入1.75亿元，占总成交额10.89%。融券方面，融券卖出4200.0股，融券偿还1000.0股，融券余量27.64万股，融券余额1108.09万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110400011044.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06127","BK0216","BK1141","BK1576","603127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680722942","title":"昭衍新药（603127）披露H股10月月报表，11月03日股价下跌9.85%","url":"https://stock-news.laohu8.com/highlight/detail?id=2680722942","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680722942?lang=zh_cn&edition=full","pubTime":"2026-11-03 22:01","pubTimestamp":1793714492,"startTime":"0","endTime":"0","summary":"截至2026年11月3日收盘，昭衍新药报收于40.09元，较前一交易日下跌9.85%，最新总市值为300.41亿元。该股当日开盘44.14元，最高44.15元，最低40.07元，成交额达16.06亿元，换手率为6.16%。近日，昭衍新药披露H股10月月报表。公告显示，截至2026年10月31日，公司H股于香港联交所上市，已发行股份为118,995,206股，无库存股份；A股未在联交所上市，已发行股份总数为630,353,014股，其中629,815,394股为已发行不包括库存股份，库存股为537,620股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110300044851.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06127","BK0216","BK1141","BK1576","603127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680745262","title":"11月3日昭衍新药跌9.85%，医疗ETF华宝基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2680745262","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680745262?lang=zh_cn&edition=full","pubTime":"2026-11-03 16:44","pubTimestamp":1793695444,"startTime":"0","endTime":"0","summary":"证券之星消息，11月3日昭衍新药跌9.85%创60日新低，收盘报40.09元，换手率6.16%，成交量38.65万手，成交额16.06亿元。根据2026基金Q3季报公募基金重仓股数据，重仓该股的公募基金共104家，其中持有数量最多的公募基金为华宝基金的医疗ETF华宝。医疗ETF华宝目前规模为243.29亿元，最新净值0.3357，较上一交易日上涨0.63%，近一年下跌9.37%。医疗ETF华宝的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110300033321.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["512170","603127","BK0216","BK1141","BK1576","06127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110257904","title":"昭衍新药更新10月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1110257904","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1110257904?lang=zh_cn&edition=full","pubTime":"2026-11-03 15:02","pubTimestamp":1793689377,"startTime":"0","endTime":"0","summary":"北京昭衍新药研究中心股份有限公司于2026年11月3日披露了截至2026年10月31日的股份变动月报表，报告显示公司股本保持稳定。此外，月报表显示，昭衍新药本月未涉及任何股份期权、股权激励计划或可换股债券等事项的增减变动。截至10月底，公司的股本总数与上月保持一致。公告同时显示，昭衍新药确认已遵守香港联合交易所有限公司《上市规则》及其他相关法律法规的规定。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105054679","title":"异动解读｜昭衍新药盘中下跌5.36%，业绩利好后资金分歧加大","url":"https://stock-news.laohu8.com/highlight/detail?id=1105054679","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1105054679?lang=zh_cn&edition=full","pubTime":"2026-11-03 11:37","pubTimestamp":1793677058,"startTime":"0","endTime":"0","summary":"11月3日，昭衍新药盘中下跌5.36%，报21.54港元，成交额5128.32万港元。近期公司消息面整体偏正面，但短线股价承压，主要反映业绩催化后市场分歧加大。同时，招银国际将其目标价上调至30港元并维持买入评级，称第三季度业绩增长明显加速。不过，同板块当日亦偏弱，药明生物、药明康德、药明合联分别下跌1.79%、2.5%和3.94%。该公司通过药物非临床研究服务、临床服务及其他、实验模型供应三大分部开展业务，主要面向中国国内和海外市场。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"昭衍新药下跌，业绩暴增后资金分歧","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680792274","title":"昭衍新药（603127）11月2日主力资金净买入4197.14万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2680792274","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680792274?lang=zh_cn&edition=full","pubTime":"2026-11-03 08:42","pubTimestamp":1793666562,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年11月2日收盘，昭衍新药报收于44.47元，下跌1.29%，换手率5.9%，成交量37.02万手，成交额16.12亿元。11月2日的资金流向数据方面，主力资金净流入4197.14万元，占总成交额2.6%，游资资金净流入2024.16万元，占总成交额1.26%，散户资金净流出6221.3万元，占总成交额3.86%。融券方面，融券卖出1.08万股，融券偿还2800.0股，融券余量27.32万股，融券余额1214.92万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110300010583.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1141","BK1576","BK0216","603127","06127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680784705","title":"招银国际：上调昭衍新药(06127.HK)目标价至30港元 维持“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2680784705","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680784705?lang=zh_cn&edition=full","pubTime":"2026-11-02 11:15","pubTimestamp":1793589321,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1576","06127","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680708784","title":"招银国际：上调昭衍新药(06127)目标价至30港元 维持“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2680708784","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680708784?lang=zh_cn&edition=full","pubTime":"2026-11-02 11:15","pubTimestamp":1793589321,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，招银国际发布研报称，将昭衍新药(06127)基于DCF模型的目标价由8.57港元上调至30港元，维持“买入”评级。公司第三季度业绩增长大幅加速。该行预计，昭衍新药2026年经调整净利润将转正至4500万元人民币，并在2027至2028年分别同比增长635.1%及58.5%，对应现阶段股价的经调整市盈率分别为331.7倍、45.1倍及28.5倍。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1516952.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["EWH","603127","06127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680207929","title":"股市必读：九州通新发布《九州通关于与北京昭衍新药研究中心股份有限公司等签订《战略合作协议》的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2680207929","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680207929?lang=zh_cn&edition=full","pubTime":"2026-11-02 02:56","pubTimestamp":1793559370,"startTime":"0","endTime":"0","summary":"股本股东变化业绩披露要点机构调研要点公司公告汇总九州通关于与北京昭衍新药研究中心股份有限公司等签订《战略合作协议》的公告2026年10月29日，九州通医药集团股份有限公司与北京昭衍新药研究中心股份有限公司、北京昭衍生物技术有限公司、生仝智能科技（北京）有限公司签订《战略合作协议》。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110200000731.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06127","600998","BK0146","BK0201","BK0216","BK1141","BK0250","BK0196","BK0187","BK0012","BK1576","603127","BK0028","BK0039","BK0183","BK0077","BK0188","BK0097"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679251472","title":"昭衍新药（603127）2026年三季报简析：营收净利润同比双双增长，盈利能力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2679251472","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679251472?lang=zh_cn&edition=full","pubTime":"2026-10-31 07:29","pubTimestamp":1793402981,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期昭衍新药发布2026年三季报。截至本报告期末，公司营业总收入11.88亿元，同比上升20.6%，归母净利润9.3亿元，同比上升1051.94%。按单季度数据看，第三季度营业总收入4.84亿元，同比上升53.01%，第三季度归母净利润1.82亿元，同比上升821.27%。本报告期昭衍新药盈利能力上升，毛利率同比增幅27.36%，净利率同比增幅855.15%。然而去年的净利率为17.97%，算上全部成本后，公司产品或服务的附加值高。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026103100016062.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603127","06127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679930211","title":"生物资产重估推高利润 昭衍新药前三季度净利增逾10倍","url":"https://stock-news.laohu8.com/highlight/detail?id=2679930211","media":"经济参考网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679930211?lang=zh_cn&edition=full","pubTime":"2026-10-30 20:23","pubTimestamp":1793363022,"startTime":"0","endTime":"0","summary":"近日，昭衍新药（603127.SH/06127.HK）披露2026年第三季度报告。数据显示，公司前三季度实现营业收入11.88亿元，同比增长20.60%；归属于上市公司股东的净利润9.30亿元，同比增长1051.94%；扣除非经常性损益后的净利润8.81亿元，同比增长2933.08%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202610303916936712.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202610303916936712.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0216","603127","06127","BK1576","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154513180","title":"异动解读｜昭衍新药盘中上涨5.51%，战略合作与业绩改善共振","url":"https://stock-news.laohu8.com/highlight/detail?id=1154513180","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1154513180?lang=zh_cn&edition=full","pubTime":"2026-10-30 13:03","pubTimestamp":1793336608,"startTime":"0","endTime":"0","summary":"10月30日，昭衍新药盘中上涨5.51%，报24.52港元，成交额8460.3万港元。消息面上，公司日前披露前三季度营收11.88亿元，同比增长20.60%；归母净利润9.30亿元，同比增长1051.94%，累计新签订单约34.2亿元，同比增长109%，在手订单约45亿元，同比增长80%。同时，九州通公告称，已与昭衍新药等签订战略合作协议，各方将围绕创新药、高端仿制药、改良型新药研发销售及AI医疗等领域合作，推动研发至商业化闭环落地。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"昭衍新药上涨，订单业绩齐爆发","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679259810","title":"昭衍新药：10月29日融资净买入2599.42万元，当日排名第49","url":"https://stock-news.laohu8.com/highlight/detail?id=2679259810","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679259810?lang=zh_cn&edition=full","pubTime":"2026-10-30 08:55","pubTimestamp":1793321700,"startTime":"0","endTime":"0","summary":"证券之星消息，10月29日，昭衍新药(603127)融资买入1.27亿元，融资偿还1.01亿元，融资净买入2599.42万元，融资余额4.8亿元，当日融资净买入排名第49。融券方面，当日融券卖出2000.0股，融券 ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20261030/c681270236.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20261030/c681270236.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["603127","BK1141","BK1576","BK0216","06127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679247467","title":"九州通最新公告：与昭衍新药等签订战略合作协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2679247467","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679247467?lang=zh_cn&edition=full","pubTime":"2026-10-29 18:06","pubTimestamp":1793268400,"startTime":"0","endTime":"0","summary":"九州通(600998.SH)公告称，公司与昭衍新药、昭衍生物、生仝智能签订《战略合作协议》，各方将在创新药、高端仿制药和改良型新药等药物研发、销售，以及早期项目投资、AI医疗、生物医药产业生态园区方面开展战略合作，打通“研发—临床—注册—商业化”闭环。本次协议为框架性文件，预计对公司2026年度经营业绩暂不构成重大影响。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102900043206.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0097","BK1576","BK0187","BK0201","06127","600998","BK0188","BK0250","BK0216","603127","BK0012","BK0183","BK0196","BK0077","BK0039","BK1141","BK0146","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111776737","title":"异动解读｜昭衍新药盘中下跌5.39%，三季报利好落地后股价回落","url":"https://stock-news.laohu8.com/highlight/detail?id=1111776737","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1111776737?lang=zh_cn&edition=full","pubTime":"2026-10-29 10:14","pubTimestamp":1793240095,"startTime":"0","endTime":"0","summary":"10月29日，昭衍新药盘中下跌5.39%，报23.18港元，成交额1.49亿港元。消息面上，公司前一日晚间披露三季报，前三季度实现营收11.88亿元，同比增长20.60%；归母净利润9.30亿元，同比增长1051.94%；其中第三季度归母净利润1.82亿元，同比增长821.27%。同时，公司披露前三季度累计新签订单约34.2亿元，同比增长109%，在手订单约45亿元，同比增长80%。尽管业绩与订单明显改善，但当日股价出现回落，反映资金在业绩发布后有所分化。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"昭衍新药盘中下跌，三季报利好兑现后回落","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678460950","title":"昭衍新药2026三季报净利暴增逾10倍，新签订单翻倍破34亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2678460950","media":"时代周报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678460950?lang=zh_cn&edition=full","pubTime":"2026-10-28 20:18","pubTimestamp":1793189921,"startTime":"0","endTime":"0","summary":"10月28日晚，昭衍新药（603127.SH/06127.HK）披露2026年三季报。前三季度公司实现营收11.88亿元，同比增长20.60%；归母净利润9.30亿元，同比大增1051.94%；扣非净利润8.81亿元，同比飙升2933.08%。第三季度单季实现营收4.84亿元，同比增长53.01%；归母净利润1.82亿元，同比增长821.27%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202610283912396282.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202610283912396282.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["603127","06127","BK1576","BK0216","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122655493","title":"昭衍新药（06127）董事会通过三季度报告并宣布11月5日举行业绩说明会","url":"https://stock-news.laohu8.com/highlight/detail?id=1122655493","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1122655493?lang=zh_cn&edition=full","pubTime":"2026-10-28 18:41","pubTimestamp":1793184106,"startTime":"0","endTime":"0","summary":"2026年10月29日，北京昭衍新药研究中心股份有限公司发布董事会决议及业绩说明会安排。公司第五届董事会第八次会议已于2026年10月28日以现场结合电话会议形式召开，11名董事全部出席，会议程序符合《中华人民共和国公司法》及公司章程规定。会后，投资者可通过上证路演中心查看本次说明会的具体情况及主要内容。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06127"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.0073},{"period":"1month","weight":-0.2063},{"period":"3month","weight":-0.0082},{"period":"6month","weight":0.1958},{"period":"1year","weight":0.2469},{"period":"ytd","weight":0.19}],"compareEarnings":[{"period":"1week","weight":0.0357},{"period":"1month","weight":-0.005},{"period":"3month","weight":-0.0631},{"period":"6month","weight":-0.0937},{"period":"1year","weight":-0.0783},{"period":"ytd","weight":-0.0668}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"北京昭衍新药研究中心股份有限公司是一家主要从事新药药理毒理学研究的中国公司。该公司通过三个分部开展业务。药物非临床研究服务分部主要提供药品非临床安全性评价服务、药效学研究服务、药代动力学研究服务。临床服务及其他分部主要提供药品上市前的临床服务以及药物警戒服务。实验模型供应分部为实验模型及其附属产品的生产和销售。该公司主要在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.052852},{"month":2,"riseRate":0.6,"avgChangeRate":0.086368},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.020373},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.07562},{"month":5,"riseRate":0.666667,"avgChangeRate":0.065576},{"month":6,"riseRate":0.666667,"avgChangeRate":0.063039},{"month":7,"riseRate":0.833333,"avgChangeRate":0.119134},{"month":8,"riseRate":0.166667,"avgChangeRate":-0.109974},{"month":9,"riseRate":0.666667,"avgChangeRate":0.056709},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.095327},{"month":11,"riseRate":0.5,"avgChangeRate":0.026794},{"month":12,"riseRate":0.6,"avgChangeRate":0.001933}],"exchange":"SEHK","name":"昭衍新药","nameEN":"JOINN"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"昭衍新药(06127)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供昭衍新药(06127)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"昭衍新药,06127,昭衍新药股票,昭衍新药股票老虎,昭衍新药股票老虎国际,昭衍新药行情,昭衍新药股票行情,昭衍新药股价,昭衍新药股市,昭衍新药股票价格,昭衍新药股票交易,昭衍新药股票购买,昭衍新药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"昭衍新药(06127)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供昭衍新药(06127)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}